A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

BACKGROUND: Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall surv...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Cancer
Asıl Yazarlar: Hirooka, Yoshiki, Kasuya, Hideki, Ishikawa, Takuya, Kawashima, Hiroki, Ohno, Eizaburo, Villalobos, Itzel B., Naoe, Yoshinori, Ichinose, Toru, Koyama, Nobuto, Tanaka, Maki, Kodera, Yasuhiro, Goto, Hidemi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2018
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5970460/
https://ncbi.nlm.nih.gov/pubmed/29801474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4453-z
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller